19th September 2019 – Global Angina
Pectoris Drugs Market is estimated to reach USD 10.6 billion by 2022
owing to the rising number of patients suffering from angina pectoris and the
probable acceptance of modern therapies like varespladib and Generx that are in
late stage of clinical development. If these modern therapies are approved,
they are expected to contribute impressively to the growth of angina pectoris
drugs industry since they will be sold at premium prices by manufacturing
companies.
When chest pain (angina) occurs,
physicians suggest blockages in heart arteries. There are many types of angina
one may have, but the major ones are chronic stable angina that occurs when the
heart is working steadily and the unstable angina which occurs when the chest
pain gets worse. The other types comprise variant angina and microvascular
angina. At present, angina pectoris treatments are not comparatively effective
and therefore newbies are experiencing new opportunities to introduce more
effective therapies and contribute the growth of angina pectoris drugs market.
The rise in chronic diseases is one of
the major growth factors for the growth of angina pectoris drugs industry.
Angina Pectoris is mainly caused by growing prevalence of chronic diseases like
high blood pressure, diabetes and obesity. High blood pressure and diabetes are
likely to develop more serious health issues associated with numerous important
organs. Obesity is the main reason for fatal cardiac disorders irrespective of
the person is suffering from high blood pressure or diabetes. The increasing
geriatric population is also projected to encourage the demand for angina
pectoris drugs in the forecast period.
Get
a Sample Copy of This Report @ https://www.millioninsights.com/industry-reports/angina-pectoris-drugs-market/request-sample
(β-blockers) β-Adrenoceptor antagonists
are suggested for the first line treatment of heart failure, arterial
fibrillation, coronary artery disease and hypertension with heart failure,
angina pectoris, or prior myocardial infarction. β-Blocker therapy is also used
in asymptomatic patients with large areas of ischemia (level IIa C evidence)
and in microvascular angina to recover effort-related angina symptoms. A
research revealed that chronic stable angina affects very less population in
the western countries with an anticipated yearly risk of death and non-fatal
myocardial infraction of comparatively less population.
Angina pectoris drugs market is categorized
on the basis of drug class, end-users, and geography. On the basis of drug
class, the market is divided into Angiotensin-converting enzyme inhibitors,
Beta-adrenergic blocking agents, Calcium channel blockers, Short & Long –
acting Nitroglycerines, Anti-ischemic agents and Antiplatelet agents. In terms
of end-users, angina pectoris drugs industry is segmented as retail pharmacies,
hospital pharmacies and online pharmacies.
Geographically, angina pectoris drugs
market is segmented as Asia Pacific, North America, Europe, South America, and
Middle East & Africa. North America is expected to dominate the market
owing to high prevalence of chronic disorders and improved healthcare
infrastructure.
The prominent players in angina pectoris
drugs industry comprise Astellas Pharma, AstraZeneca PLC, Ark Therapeutics
Group plc, Cardium Therapeutics, Cardeus Pharmaceuticals,
CardioVascularBioTherapeutics (CVBT), HUYA Bioscience International LLC,
Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd, Korea Otsuka
Pharmaceutical Co.Ltd, Pfizer, Inc., Baxalta US Inc., Gilead Sciences, Inc,
Sanofi SA, and TSH Biopharm Corporation Limited.
Get
in touch
At Million Insights, we work with the
aim to reach the highest levels of customer satisfaction. Our representatives strive
to understand diverse client requirements and cater to the same with the most
innovative and functional solutions.
For
More Information, Visit @ https://www.millioninsights.com
No comments:
Post a Comment